What is your approach to patients who experience widespread progression on EGFR inhibitors found to have MET amplification on tumor biopsy in addition to sensitizing EGFR mutation?

Ideally, speaking they should be enrolled in clinical trials with a bispecific antibody for EGFR and CMET or drugs targeting CMET with continued EGFRi. There is a paucity of data on continuing Osimertinib on progression with Crizotinib or Capamatinib. In clinical practice, chemo or chemoIO is also a...

Amivantamab off label once it is approved in Exon 20 mutation. Combination with Lazertinib is safe per CHRYSALIS, but the current trial appears to be in the frontline.